Real world seems to confirm clinical trial data in this case!
A real-world study from the IRONMAN registry confirms that achieving an undetectable PSA nadir (<0.2 ng/mL) within the first year of treatment is linked to better long-term outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Among 1,377 patients, those treated with ADT + ARPI had the highest PSA suppression rates (51% at 6 months, 63% at 12 months), outperforming ADT alone (27% and 38%) and ADT + docetaxel (26% and 32%).
After a median follow-up of 18 months, 21% of patients experienced disease relapse, with lower relapse rates in those who reached PSA nadir <0.2 ng/mL at 6 months.